Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 22, 2013
Event: Completion of a Share Exchange Agreement with Actinium Corporation.
Key Financial Metrics and Transaction Details
This filing reports a specific corporate transaction rather than standard periodic financial performance metrics (revenue, profit, cash flow). The filing text does not provide current revenue, profit, or liquidity figures for the reporting period.
- Transaction Type: Share Exchange (Acquisition of equity).
- Shares Acquired: 24,052,702 shares of Actinium Corporation capital stock.
- Consideration Issued: 8,009,550 shares of Actinium Pharmaceuticals, Inc. Common Stock.
- Ownership Stake: The acquired shares represent 38.2% of Actinium Corporation's issued and outstanding equity.
- Total Ownership: As of August 22, 2013, the Company owns approximately 93.7% (59,047,916 shares) of Actinium Corporation.
Material Changes Versus Prior Period
The filing details a significant increase in ownership of Actinium Corporation compared to the prior transaction disclosed in January 2013.
- Prior Transaction (Dec 2012/Jan 2013): The Company previously acquired 21% of Actinium Corporation in exchange for 4,309,015 shares.
- Current Transaction (Aug 2013): The Company acquired an additional 38.2% stake.
- Resulting Control: Following the January 2013 transaction, former Actinium Corporation shareholders became the controlling shareholders of Actinium Pharmaceuticals, Inc., and Actinium Corporation's directors and officers were appointed to the Company's Board and executive roles.
Guidance, Outlook, and Risks
Outlook: The Company intends to continue exchanging its common stock for shares of Actinium Corporation held by the remaining shareholders to achieve full ownership.
Regulatory Compliance: The shares issued in this transaction were sold in a private transaction relying on exemptions from registration under Section 4(2) of the Securities Act, Rule 506 of Regulation D, and Regulation S. Investors were represented as "accredited investors."
Financial Statements: The filing incorporates by reference audited financial statements for Actinium Corporation for years ended Dec 31, 2011 and 2010, and unaudited interim statements for periods ended Sept 30, 2012 and 2011. Unaudited pro forma combined financial information is also included as an exhibit.
Investor Verification Checklist
- Verify the total number of outstanding shares of Actinium Pharmaceuticals, Inc. post-transaction to assess dilution impact.
- Review the attached Audited Consolidated Financial Statements (Exhibit 99.1) and Unaudited Interim Statements (Exhibit 99.2) for Actinium Corporation to understand the acquired entity's financial health.
- Examine the Unaudited Pro Forma Combined Financial Information (Exhibit 99.3) to understand the projected financial position of the combined entity.
- Confirm the timeline and terms for the remaining 6.3% of Actinium Corporation shares not yet acquired.